Procedure

LG LAUNCHES PORTABLE AND RUGGED XBOOM GO XG8T AND XG2T WIRELESS SPEAKERS

Retrieved on: 
Giovedì, Maggio 9, 2024
IP67, Immersion, Vibration, System, Fresh water, Element, Android, IEC, Hand, LG, Water, Compatibility, Dust, Procedure, Sound, LED, Category, Bass, Rain, Algorithm, IOS, Transformer

ENGLEWOOD CLIFFS, N.J., May 9, 2024 /PRNewswire/ -- LG Electronics USA (LG) today announced pricing and availability for the newest additions to its portable speaker lineup with the XBOOM Go XG8T and XBOOM Go XG2T Wireless Bluetooth Speakers. Fit for any adventure, the XG8T and XG2T deliver robust sound packed into durable, compact and portable designs. The XG8T ($379.99) and the XG2T ($79.99) are available to purchase today at LG.com and select LG-authorized retailers.

Key Points: 
  • ENGLEWOOD CLIFFS, N.J., May 9, 2024 /PRNewswire/ -- LG Electronics USA (LG) today announced pricing and availability for the newest additions to its portable speaker lineup with the XBOOM Go XG8T and XBOOM Go XG2T Wireless Bluetooth Speakers.
  • Fit for any adventure, the XG8T and XG2T deliver robust sound packed into durable, compact and portable designs.
  • The XG8T and XG2T speakers have passed seven military standard tests, withstanding high temperatures, rain, salt fog, dust, and even water immersion and shock1.
  • From the beach to the mountains, the XG8T and XG2T are built to be enjoyed almost anywhere.

Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update

Retrieved on: 
Giovedì, Maggio 9, 2024
FDA, Fast Track, Research, Rett syndrome, Trial of the century, Partnership, Doctor of Philosophy, Conference call, CNS, Procedure, Frontotemporal dementia, EDGAR, Food, Orphan drug, European Medicines Agency, Brain, RWE, MECP2, Drug development, RNA-Seq, Conference, Publication, Pharmacokinetics, U.S. FDA, Marketing authorisation, DSM-IV codes, Patent, Real, RNA, Human, Therapy, Treatment, EMA, Alzheimer's disease, Central nervous system, Clinical trial, Medicine, Marketing, ADAS, Centralisation, Pharmacology, European, Patient, Expanded access, Caregiver, Webcast, Interim, Bank statement, Pharmaceutical industry

NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsychiatric disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia, and other central nervous system (CNS) diseases, today reported financial results for its fiscal quarter ended March 31, 2024.

Key Points: 
  • Parkinson’s disease: Initiation of ANAVEX®2-73 imaging-focused trial and Phase 2b/3 6 month trial is expected in the second half of 2024.
  • General and administrative expenses for the quarter of $2.8 million compared to $2.9 million for the comparable quarter of fiscal 2023.
  • Research and development expenses for the quarter of $9.7 million compared to $11.3 million for the comparable quarter of fiscal 2023.
  • The financial information for the fiscal quarter ended March 31, 2024, should be read in conjunction with the Company’s condensed consolidated interim financial statements, which will appear on EDGAR, www.sec.gov and will be available on the Anavex website at www.anavex.com .

DrFirst Acquires Myndshft Technologies to Revolutionize Medication Management by Addressing Both Pharmacy and Medical Benefits

Retrieved on: 
Giovedì, Aprile 18, 2024
Pharmacy, Procedure, AI, Machine learning, Health care, EHR, Electronic health record, Insurance, Software as a service, RPA, Patient, PAS, Acquisition, Physician, Pharmaceutical industry

ROCKVILLE, Md., April 18, 2024 /PRNewswire/ -- Healthcare technology pioneer DrFirst today announced it has acquired substantially all assets of Myndshft Technologies, Inc., a leader of end-to-end real-time medical benefits and automated prior authorization (PA) software-as-a-service (SaaS). This strategic acquisition aims to improve the patient experience and expedite access to vital specialty medications, such as infusions and in-office injectables primarily covered by medical benefits. Combined with DrFirst's platform and scale, the technology will also lighten the substantial administrative load on healthcare providers and their staff.

Key Points: 
  • This strategic acquisition aims to improve the patient experience and expedite access to vital specialty medications, such as infusions and in-office injectables primarily covered by medical benefits.
  • Founded in 2018, Myndshft is the only unified platform that streamlines prior authorization and related services for both medical and pharmacy benefits.
  • The Myndshft platform also supports labs, imaging, and other procedures covered under medical benefits, which are often prerequisites for patients prescribed specialty medications.
  • "The category of insurance benefit – pharmacy vs. medical – should not dictate a lower level of transparency or efficiency for prior authorizations.

United States Architecture, Engineering and Construction (AEC) Firm Policies, Procedures & Benefits Report 2023 - ResearchAndMarkets.com

Retrieved on: 
Lunedì, Aprile 8, 2024
Engineering, Architecture, Construction & Property, Manufacturing, AEC, Education, Procedure, HR, Policy, Management

The "2023 Policies, Procedures & Benefits Report of AEC Firms" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "2023 Policies, Procedures & Benefits Report of AEC Firms" report has been added to ResearchAndMarkets.com's offering.
  • The results of this study will help you benchmark your AEC firm in all areas related to benefits and compensation.
  • The 2023 Policies, Procedures & Benefits Survey Report of AEC Firms provides you with industry statistics on policies and procedures, so you can support your policy decisions with hard data.
  • The data presented in the 2023 Policies, Procedures & Benefits Survey Report is broken down by firm type, size, region, and other important factors, so you can make accurate comparisons between your firm and others.

GuidePoint Security Helps Organizations Address Data Privacy Requirements with Portfolio of Services

Retrieved on: 
Giovedì, Marzo 21, 2024
Data Management, Security, Technology, Software, Networks, Internet, Metric, Organization, Exercise, Digital, Information, Risk, U.S. state, GDPR, DSAR, Process, PET, Bill of Rights, IPO, GPC, Privacy, NIST, Architecture, HIPAA, Do Not Track, FERPA, Procedure, ISO, Federal, Legislation, Guidepoint, Online shopping

GuidePoint Security , a cybersecurity solutions leader enabling organizations to make smarter decisions and minimize risk, today announced the availability of its Data Privacy services, which are designed to help customers take control of their privacy operations.

Key Points: 
  • GuidePoint Security , a cybersecurity solutions leader enabling organizations to make smarter decisions and minimize risk, today announced the availability of its Data Privacy services, which are designed to help customers take control of their privacy operations.
  • These new data privacy laws will require companies to be accountable and to evaluate and ensure data protection addendums in their processes.
  • GuidePoint’s Data Privacy Services are tailored to meet an organization and its data privacy program at its current maturity level.
  • “We have developed a broad portfolio of data privacy services to meet a customer at their current maturity level,” said Scott Griswold, Practice Director - Governance Services, GuidePoint Security.

Global Pediatric Interventional Cardiology Market Forecast 2024-2030: PIC Market Forecast for 6.36% CAGR Between 2024 to 2030 - ResearchAndMarkets.com

Retrieved on: 
Giovedì, Febbraio 29, 2024
General Health, Health, Cardiology, Heart, Incidence, Procedure, Catheter, Birth defect, Investment, Physician, Moyamoya disease, Congenital heart defect, Projection, VSD, Angioplasty, Prevalence, CHD, Coronary thrombosis, Atherectomy, Patient, Stent, Ventricular septal defect, CDC, Catheter ablation, Research, Medical imaging

The Pediatric Interventional Cardiology Market is forecasted to reach US$ 3.91 Billion through 2030.

Key Points: 
  • The Pediatric Interventional Cardiology Market is forecasted to reach US$ 3.91 Billion through 2030.
  • The pediatric interventional cardiology market proportion is expanding swiftly, driven by the rising prevalence of cardiac disorders in children and technological advancements.
  • The Stents segment is anticipated to dominate the global pediatric interventional cardiology market throughout the forecast period.
  • The comprehensive infrastructure of hospitals, coupled with their ability to provide diverse pediatric cardiology services, positions them as key contributors to the growth and development of the Pediatric Interventional Cardiology market.

Global Clear Aligner Market Analysis and Forecast to 2029: Compound Annual Growth of 22% Forecast During 2024-2029, Driven by Growing Patient Population Suffering from Malocclusions - ResearchAndMarkets.com

Retrieved on: 
Lunedì, Febbraio 19, 2024
Dental, Health, Incidence, Codd-neck bottle, Procedure, Malocclusion, Dentist, Growth, Treatment, Dentistry, Orthodontics, Urbanization, Dental care, Stand-alone, Prevalence, CAD, GNI, COVID-19, Age, Platform, Disease, Ageing, Insurance

The global clear aligner market was valued at US$5.56 billion in 2023.

Key Points: 
  • The global clear aligner market was valued at US$5.56 billion in 2023.
  • An increase in the incidence of periodontitis would support the growth of the clear aligner market in Europe.
  • The rising prevalence of malocclusion cases is positively affecting the demand for the clear aligner and hence, boosting the market growth.
  • Thus, the growing dental tourism is expected to stimulate the demand for clear aligners in the coming years.

Questions and answers on the European Union framework for (traditional) herbal medicinal products, including those from a ‘non-European’ tradition

Retrieved on: 
Domenica, Marzo 10, 2024
Well, DER, Fungus, Capsule, TUR, Interest, Animal, Part, Exercise, Database, Viral, Hepatitis, Powder, Collection, Directive, Union, Nutrient, DSM-IV codes, Volume, CTD, Legislation, Literature, Fermentation, Diabetes, Pharmacopoeia, Inhalation, Committee, Monograph, NTA, WEU, DCP, AIDS, See, Mineral, Marketing, Safety, Plant, MRA, Autoimmunity, Directive 2001/83/EC, GMP, Documentation, Seed, Heart failure, Distillation, CHMP, MRP, European Medicines Agency, Guideline, Disorder, Mutual, Convention, State, Tablet, Community, Clinical trial, Rapporteur, European Commission, Woman, Medication package insert, Vitamin, Quality, Authority, GACP, SAWP, Pharmacovigilance, Civil service commission, HMPS, Science, Health, Bibliography, Section 4, Infection, Kampo, Commission, Abbreviation, Pathology, Prescription, Human, Medication, Reproduction, EMA, NCA, Chapter One, EDQM, TAM, European Pharmacopoeia, European Economic Area, Food, Regulation (European Union), COM, TCM, Administration, Mutual recognition, Procedure, Medicine, Herbal, Answer, Q&A, HIV, EudraLex, Cancer, Public, Medicinal plants

1

Key Points: 
    • 1
      Committee on Herbal Medicinal Products (HMPC)

      Questions & Answers on the European Union framework
      for (traditional) herbal medicinal products, including those
      from a ?non-European? tradition

      Table of Content
      1.

    • European Pharmacopoeia

      SAWP

      Scientific Advice Working Party

      SmPC

      Summary of Product Characteristics

      THMP

      Traditional Herbal Medicinal Product

      TUR

      Traditional Use Registration

      WEU

      Well-Established Use

      Questions & Answers on the European Union framework for (traditional) herbal
      medicinal products, including those from a ?non-European? tradition
      EMA/HMPC/402684/2013 Rev.

    • Terminology of herbal medicinal products (Q&A 1-4)

      Question 1
      What are herbal substances, herbal preparations, and herbal medicinal products?

    • Questions & Answers on the European Union framework for (traditional) herbal
      medicinal products, including those from a ?non-European? tradition
      EMA/HMPC/402684/2013 Rev.
    • Question 4
      Are food supplements regulated under the European Union (EU) pharmaceutical legislation
      for (traditional) herbal medicinal products ((T)HMPs)?
    • Questions & Answers on the European Union framework for (traditional) herbal
      medicinal products, including those from a ?non-European? tradition
      EMA/HMPC/402684/2013 Rev.
    • Regulation of herbal medicinal products in the European Union (Q&A 511)

      Question 5
      Where to find the pharmaceutical legislation and dossier requirements for herbal medicinal
      products (HMPs), including traditional herbal medicinal products (THMPs), in the European
      Union (EU)?

    • Questions & Answers on the European Union framework for (traditional) herbal
      medicinal products, including those from a ?non-European? tradition
      EMA/HMPC/402684/2013 Rev.
    • These countries have,
      through the EEA agreement, adopted the complete Union acquis on medicinal products and are
      consequently parties to the Union procedures.
    • Questions & Answers on the European Union framework for (traditional) herbal
      medicinal products, including those from a ?non-European? tradition
      EMA/HMPC/402684/2013 Rev.
    • Questions & Answers on the European Union framework for (traditional) herbal
      medicinal products, including those from a ?non-European? tradition
      EMA/HMPC/402684/2013 Rev.
    • Questions & Answers on the European Union framework for (traditional) herbal
      medicinal products, including those from a ?non-European? tradition
      EMA/HMPC/402684/2013 Rev.
    • Questions & Answers on the European Union framework for (traditional) herbal
      medicinal products, including those from a ?non-European? tradition
      EMA/HMPC/402684/2013 Rev.
    • Specific provisions for traditional herbal medicinal products (Q&A 1221)

      Question 12
      Which indications can be granted for traditional herbal medicinal products (THMPs)?

    • Questions & Answers on the European Union framework for (traditional) herbal
      medicinal products, including those from a ?non-European? tradition
      EMA/HMPC/402684/2013 Rev.
    • Nov. 2023
      Answer 17

      Questions & Answers on the European Union framework for (traditional) herbal
      medicinal products, including those from a ?non-European? tradition
      EMA/HMPC/402684/2013 Rev.

    • Questions & Answers on the European Union framework for (traditional) herbal
      medicinal products, including those from a ?non-European? tradition
      EMA/HMPC/402684/2013 Rev.
    • Question 29
      Does the Committee on Herbal Medicinal Products (HMPC) hold a specific database on
      (registered) authorised (traditional) herbal medicinal products ((T)HMPs)?
    • Discussion with Member States intended to be

      Questions & Answers on the European Union framework for (traditional) herbal
      medicinal products, including those from a ?non-European? tradition
      EMA/HMPC/402684/2013 Rev.

    • Questions & Answers on the European Union framework for (traditional) herbal
      medicinal products, including those from a ?non-European? tradition
      EMA/HMPC/402684/2013 Rev.

CH4 Global welcomes FDA move on animal feed additives

Retrieved on: 
Giovedì, Febbraio 8, 2024
Agriculture, Methane, Policy, Cattle, FDA, Food, Climate change, Innovation, Congress, Farmer, Animal, Legislation, Procedure, Water, Habit

HENDERSON, Nev., Feb. 8, 2024 /PRNewswire/ -- CH4 Global today issued the following statement regarding the announcement by the U.S. Food and Drug Administration (FDA) that it plans to withdraw a policy that caused multi-year approval delays for certain animal-feed additives that can produce beneficial effects via animal digestive systems:

Key Points: 
  • This vital step by the FDA demonstrates a commitment to modernizing regulations around animal food additives, marking a major milestone for U.S. agriculture that brings our company closer to being able to commercialize our innovative feed additive in the United States.
  • The FDA's decision to encourage early engagement with companies developing novel animal foods is a positive move for farmers, consumers, and efforts to mitigate climate change.
  • In light of this positive regulatory development, CH4 Global continues to call on Congress to provide additional clarity by passing the Innovative FEED Act without delay.
  • Passage of the Innovative FEED Act will establish a clear and transparent regulatory process, not only supporting companies like CH4 Global in bringing innovative products to market, but also bolstering the global competitiveness of U.S. farmers while reducing regulations in line with other countries.

U.S Architecture, Engineering, Construction (AEC) Firms Gain Strategic Edge with 2023 Future Owners Bundle Report - ResearchAndMarkets.com

Retrieved on: 
Lunedì, Gennaio 22, 2024
Engineering, Architecture, Construction & Property, Manufacturing, Culture, Procedure, Partner, Benchmarking, AEC, Growth, Management

The "2023 Future Owners Bundle Report of U.S Architecture, Engineering, Construction (AEC) Firms" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "2023 Future Owners Bundle Report of U.S Architecture, Engineering, Construction (AEC) Firms" report has been added to ResearchAndMarkets.com's offering.
  • A comprehensive research suite, titled the "2023 Future Owners Bundle Report," has been meticulously assembled to empower U.S AEC Firms with unmatched insights and strategic understanding of firm performance, culture, and productivity.
  • The 2022 Principals, Partners & Owners Report offers detailed compensation analytics and insights into the roles and expectations of the upper echelons in AEC firms.
  • With its unveiling, the "2023 Future Owners Bundle Report" takes a central place among the vital resources for industry leaders tasked with steering their firms towards a prosperous future in the vibrant world of architecture, engineering, and construction.